# PROUD-PV: HCP commentary report > 33 HCP sources screened · 749 verified claims from 32 sources · 11 findings. Updated 2026-10-08. ## Report - Trial: A Randomized, Open-label, Multicenter, Controlled, Parallel Arm, Phase III Study Assessing the Efficacy and Safety of AOP2014 vs. Hydroxyurea in Patients With Polycythemia Vera - NCT ID: NCT01949805 - Registry: https://clinicaltrials.gov/study/NCT01949805 - Sponsor: AOP Orphan Pharmaceuticals AG - Phase: Phase 3 - Status: Completed - Drugs: ropeginterferon alfa-2b, hydroxyurea - Indications: Polycythemia vera - Version: v1.0.0, edition 1 - Accepted: 2026-10-08 - Last checked: 2026-10-08 - Release hash: 7aa5a3fbfde5fc27a135d21399ccb79d14d11072ca035eef11595dc112da7630 ## Counts - HCP commentary sources screened: 33 - Sources cited by verified claims: 32 - Verified claims: 749 - Findings: 11 - People found in screened sources: 44 - People identity-verified: 26 - Voices cited: 33 Counts describe the retained sources. They do not estimate how many HCPs hold a view. ## Abstract PROUD-PV raises a central clinician question: does ropeginterferon offer meaningful long-term benefit compared with hydroxyurea for people with polycythemia vera who need blood-count control? Clinicians discuss molecular response and its clinical relevance, early versus extended follow-up, comparator treatment and extension design, and selection of patients for cytoreduction. Other topics include dose escalation, psychiatric and autoimmune safety, monitoring and treatment-free periods, diagnostic work-up and risk assessment, alternative treatments, and the implications for patient counseling, access and support. ## Open Medical Affairs question What evidence would make molecular response actionable after blood counts normalize? ## Findings (titles) - F1. Molecular response is gaining clinical meaning, but its role in changing treatment remains contested - F2. Earlier cytoreduction in low-risk PV attracts support, but deferral remains an active-management position - F3. The favorable reading is time-dependent and must remain beside the early endpoint and extension qualifications - F4. Improved tolerability does not remove psychiatric, autoimmune or organ-specific selection and stopping concerns - F5. Faster titration is an unanswered benefit–toxicity trade-off, not a proven route to better clinical outcomes - F6. Treatment-free periods are selective experiences, not a routine promise or evidence of cure - F7. Hydroxyurea remains a credible choice; interferon preference is shaped by time horizon, patient priorities and specific constraints - F8. Risk assessment and diagnostic work-up are treated as conditions for therapy, not as a single age or laboratory cutoff - F9. Ruxolitinib is a symptom- and failure-driven alternative, with upfront positioning and long-exposure safety still questioned - F10. Rusfertide is discussed chiefly as an adjunct or bridge, not as a substitute for anticlonal treatment - F11. Patient expectations, access and research support are part of the treatment conversation ## Sample findings ### F1. Molecular response is gaining clinical meaning, but its role in changing treatment remains contested An X thread asked whether molecular response during ropeginterferon treatment, including a fall in JAK2 allele burden, translates into a change in the course of PV. Source: X thread, 2023-12-10. ### F3. The favorable reading is time-dependent and must remain beside the early endpoint and extension qualifications A podcast speaker asked whether an abstract concerned the original PROUD-PV study, its CONTINUATION-PV extension or a particular component of longer-term follow-up. Source: podcast, 2024-09-13. ## Trial aspects | Aspect | Coverage | Claims | Sources | | --- | --- | ---: | ---: | | Primary endpoint: Disease response rate | discussed | 11 | 6 | | Secondary endpoints | discussed | 18 | 9 | | Population and setting | discussed | 21 | 12 | | The comparison | discussed | 22 | 8 | | Safety and tolerability | discussed | 35 | 11 | | Design and conduct | discussed | 22 | 8 | | Clinical meaning and actionability of JAK2 molecular response | discussed | 35 | 12 | | Adding cytoreduction in conventionally low-risk PV | discussed | 50 | 8 | | Early response versus sustained benefit and extension interpretation | discussed | 30 | 9 | | Interferon safety, controlled comorbidity and rechallenge | discussed | 39 | 8 | | Titration speed, individualization and response–toxicity balance | discussed | 46 | 9 | | Molecular monitoring, assay sensitivity and treatment-free periods | discussed | 59 | 11 | | Hydroxyurea versus interferon: preferences and constraints | discussed | 70 | 14 | | Diagnosis, progression risk and count targets informing selection | discussed | 70 | 12 | | Ruxolitinib as an alternative and its upfront evidence question | discussed | 46 | 6 | | Rusfertide adjunctive or bridge use and iron-handling uncertainty | discussed | 29 | 5 | | Counseling, access, patient support and future treatment questions | discussed | 65 | 14 | ## Cited sources by channel - Podcasts: 11 - Publications: 2 - X threads: 6 - YouTube: 13 ## Scope and limits This report does not judge efficacy, estimate HCP prevalence or consensus, give treatment advice. - Sources were found by searching for the trial's name, registry number and known aliases. Discussion that refers to the trial without naming it may be missing. - For 2 recordings, a transcript separated by speaker was not available, so quotes come from the original automatic transcript and may lack speaker labels. - 22 points raised by the independent review are not yet resolved in this edition, such as a clinician view not yet captured as evidence or a qualifier to restore. The next refresh takes them up. - 13 further source limits are recorded in the machine-readable scope of this record. - Coverage is limited to the reviewed material. Some relevant recordings could not be accessed, and discussion using unnamed trial references or unfamiliar name variants may be absent. - Several sources contain the same conversation in different formats. Their repetition is not independent clinical corroboration, and source counts do not represent independent HCP counts. - Study outcomes, guideline descriptions, approval statements and dosing practices are generally reported by speakers. They remain attributed accounts rather than independently established trial results or prescribing guidance. - Some passages have incomplete sentences, uncertain measures or unclear clinical direction. The report does not supply a missing direction, threshold or referent. - Some speakers are identifiable only by a first name or remain unnamed. John, Toyosi and Tony are retained as established in their respective passages; a fuller identity is not inferred. Elissa Baldwin is retained as a host whose clinical role is unresolved in the supplied professional context. - Comments span different events and publication dates. The EHA22 debate was published in March 2023; later favorable posts or discussions do not establish a change of mind or disagreement across settings. - The supplied primary ancillary analysis was small and preliminary, and its clinical-outcome caveat belongs to that analysis’s period. It neither proves clinical benefit from molecular reduction nor negates later speaker-reported associations. ## Offer - Size: Standard (30 commentary sources cited) - Current edition: $1,250. Buy it below; a purchase starts a check for new commentary and any newer edition follows at no charge - 3 months of weekly updates: $2,200 - 6 months of weekly updates: $3,100 - 12 months of weekly updates: $4,400 - Optional identity linkages (12-month updates only, product updates-12-identities; speakers are named and described in every report): NPI and other verified IDs at $15 per identity-verified person in the edition at purchase (26 now), at most $1,250; people verified later in the term at no charge - Pricing: https://www.erudio.com/pricing - Buy now (card, through Stripe): https://www.erudio.com/reports/proud-pv-nct01949805 - Agents: POST https://www.erudio.com/api/orders with {"report": "proud-pv-nct01949805", "product": "edition" | "updates-3" | "updates-6" | "updates-12" | "updates-12-identities", "buyer_email": "...", "licence_key": ""}; it returns a payment link for your user (and a pay_url your own MPP or x402 payment client can pay over HTTP 402, when offered), and once paid the status_url returns your licence key. Send the same key with every later order so all reports sit on one key. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST https://www.erudio.com/api/keys/recover) sends it again - Talk to Tom and Audun (invoice, PO, questions): https://www.erudio.com/contact?report=proud-pv-01949805 ## Cite Erudio Health. PROUD-PV (NCT01949805): HCP commentary report. Edition 1, v1.0.0. Accepted 2026-10-08. https://www.erudio.com/reports/proud-pv-nct01949805 ## Machine access - JSON: https://www.erudio.com/reports/proud-pv-nct01949805.json - MCP: https://mcp.erudio.com/mcp, tool `get_report_card` with `{"slug": "proud-pv-01949805"}`